What is romiplostim (Nplate) and how does it work in the treatment of immune (idiopathic) thrombocytopenic purpura?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Romiplostim and How Does It Work in ITP

Romiplostim (Nplate) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating TPO receptors on megakaryocytes, indicated for adult and pediatric ITP patients (≥1 year old with ≥6 months disease duration) who have failed corticosteroids, immunoglobulins, or splenectomy 1.

Mechanism of Action

Romiplostim is an Fc-peptide fusion protein (peptibody) that works fundamentally differently from traditional ITP therapies:

  • Direct platelet production stimulation: Unlike corticosteroids or immunoglobulins that suppress immune destruction, romiplostim directly stimulates megakaryopoiesis and thrombopoiesis by activating TPO receptors 2, 3
  • No sequence homology to native TPO: This design avoids the theoretical risk of generating cross-reacting neutralizing antibodies against endogenous thrombopoietin 2
  • Additional immunomodulatory effects: Recent evidence suggests romiplostim may have immunomodulatory properties beyond simple platelet production 4

Clinical Positioning

Per ASH 2019 guidelines, romiplostim is recommended as a second-line option for ITP lasting ≥3 months in patients who are corticosteroid-dependent or unresponsive 5. The guidelines suggest either eltrombopag or romiplostim as TPO-RA options, with choice based on patient preference for weekly subcutaneous injections versus daily oral medication 5.

Treatment Algorithm for Second-Line ITP:

  • TPO-RA (romiplostim or eltrombopag) vs. splenectomy vs. rituximab are all conditional recommendations
  • TPO-RA is suggested over rituximab when comparing these two options directly 5
  • Rituximab is suggested over splenectomy for patients preferring to avoid surgery 5

Dosing and Administration

Starting dose: 1 mcg/kg subcutaneously once weekly, adjusted by 1 mcg/kg increments based on platelet response (maximum 10 mcg/kg/week) 1:

  • Target platelet count: ≥50 × 10⁹/L to reduce bleeding risk—not normalization of counts 1
  • Dose adjustments:
    • If platelets <50 × 10⁹/L: increase by 1 mcg/kg
    • If platelets 200-400 × 10⁹/L for 2 weeks: reduce by 1 mcg/kg
    • If platelets >400 × 10⁹/L: hold dose, resume at reduced dose when <200 × 10⁹/L
  • Monitoring: Weekly CBC during dose adjustment, then monthly once stable 1
  • Discontinuation criteria: If no adequate response after 4 weeks at maximum dose (10 mcg/kg) 1

Important Caveat on Initial Dosing:

Recent real-world data shows that higher initial doses (≥3 mcg/kg) do not accelerate platelet response compared to standard low-dose initiation (<3 mcg/kg), with both achieving response at median 7 days 6. Stick with the FDA-approved 1 mcg/kg starting dose.

Efficacy

Romiplostim demonstrates robust efficacy in both splenectomized and non-splenectomized patients:

  • Durable platelet response: 61% in non-splenectomized vs. 38% in splenectomized patients (compared to 5% and 0% with placebo, respectively) 2, 7
  • Overall response rate: 83% achieved any platelet response 7
  • Time to response: Median ~2 weeks, with most patients maintaining response on median dose of 2-3 mcg/kg 1, 2
  • Long-term maintenance: Real-world data shows sustained platelet counts between 10-12 × 10⁴/µL from 8-104 weeks of treatment 8

Sustained Remission After Discontinuation:

A notable finding is that 15-48% of patients maintain platelet responses after romiplostim discontinuation 9. Key observations:

  • In the Newland study, 32% of recently-diagnosed ITP patients achieved remission (platelets ≥50 × 10⁹/L for 24 weeks) after romiplostim discontinuation 9
  • Sustained responses maintained for median 20-33 months in various cohorts 9
  • No predictive factors identified for who will maintain remission 9

Clinical implication: Consider attempting gradual taper and discontinuation once stable platelet counts achieved, with close monitoring (weekly CBC for ≥2 weeks post-discontinuation) 1.

Safety Profile

Romiplostim is generally well-tolerated with mostly mild-to-moderate adverse events 2:

Common adverse reactions (≥5% higher than placebo in adults): arthralgia, dizziness, insomnia, myalgia, extremity pain, abdominal pain, shoulder pain, dyspepsia, paresthesia, and headache 1

In pediatric patients (≥25%): contusion, upper respiratory tract infection, oropharyngeal pain 1

Critical Safety Warnings:

  1. Contraindicated in MDS: Romiplostim increases blast counts and progression risk to acute myelogenous leukemia in myelodysplastic syndrome patients 1

  2. Thrombotic/thromboembolic risk: Particularly concerning in chronic liver disease patients (portal vein thrombosis reported) 1

  3. Rebound thrombocytopenia: Worsened thrombocytopenia can occur after discontinuation—requires weekly monitoring for ≥2 weeks post-stop 1

  4. Bone marrow reticulin formation: Risk identified in FDA review 10

  5. Neutralizing antibodies: If severe thrombocytopenia develops during treatment, assess for antibody formation 1

Real-world discontinuation rates: 14.92% discontinued due to adverse events within 2 years, while 14% discontinued due to symptom improvement 8.

Quality of Life Impact

Romiplostim significantly improves patient outcomes beyond platelet counts:

  • Reduced bleeding events: Significant bleeding decreased from 76.9% to 34.6% 11
  • Decreased healthcare utilization: Hospital admissions dropped from 69.2% to 7.7%, rescue medication use from 65.4% to 11.5% 11
  • Improved HRQoL: Platelet counts positively correlated with health-related quality of life in pediatric patients 11

Practical Considerations

  • Access: Must be ordered through manufacturer's limited access program (Risk Evaluation and Mitigation Strategy) 12, 10
  • Administration: Requires clinic visits for weekly subcutaneous injections 12
  • Dose precision: Very small volumes may be required—use syringes with 0.01 mL graduations 1
  • Sequential TPO-RA use: Romiplostim remains effective even in patients who failed eltrombopag 11

References

Research

Romiplostim.

Drugs, 2009

Research

The development of romiplostim for patients with immune thrombocytopenia.

Annals of the New York Academy of Sciences, 2011

Research

Evaluation of the efficacy and safety of initial high-dose romiplostim for primary immune thrombocytopenia in the acute care setting.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2026

Research

Romiplostim management of immune thrombocytopenic purpura.

The Annals of pharmacotherapy, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.